Education
About Us
Working with TipRanks
Follow Us
MetaVia (MTVA)
NASDAQ:MTVA
MTVA Stock Chart & Stats
$5.42
-$0.13(-5.60%)
At close: 4:00 PM EST
$5.42
-$0.13(-5.60%)
Day’s Range― - ―
52-Week Range$5.23 - $23.87
Previous CloseN/A
Volume36.62K
Average Volume (3M)3.42M
Market Cap
$12.51M
Enterprise Value-$7.66M
Total Cash (Recent Filing)$17.59M
Total Debt (Recent Filing)$98.00K
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 26, 2026EPS Estimate
-1.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding2,308,294
10 Day Avg. Volume118,677
30 Day Avg. Volume3,419,960
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)21.84
Price to Sales (P/S)0.00
P/FCF Ratio-7.01
Enterprise Value/Market Cap-0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit403.06
Enterprise Value/Ebitda0.48
Forecast
1Y Price Target
$47.50Price Target Upside776.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DataPhase 1b results showed DA-1726 produced rapid weight loss, reduced waist circumference, improved glycemic measures, and demonstrated a signal of reduced liver stiffness while maintaining a favorable safety and tolerability profile, supporting its therapeutic potential in obesity and related liver disease.
Combination Therapy PotentialVanoglipel combined with a DPP4 inhibitor extended therapeutic effect and lowered HbA1c, indicating a viable combination approach to enhance metabolic control and liver outcomes.
Development PartnershipsManagement's active search for a development partner to co-develop regimens targeting deeper histologic improvement creates a clearer path toward regulatory registration and could strengthen the commercial outlook for the pipeline.
Bears Say
Differentiation RiskDA-1726 risks being perceived as a me-too monotherapy without clear clinical differentiation or a credible combination strategy, which could limit uptake and long-term revenue potential.
Market CompetitionThe obesity treatment market is crowded with oral competitors and potential new approvals, increasing convenience and pricing expectations that could compress commercial opportunities for new entrants.
Valuation PressureShares may face ongoing valuation pressure as investor sentiment favors larger competitors in obesity and liver disease, reducing appetite for smaller specialized players and increasing stock volatility.
MetaVia News
MTVA FAQ
What was MetaVia’s price range in the past 12 months?
MetaVia lowest stock price was $5.23 and its highest was $23.87 in the past 12 months.
What is MetaVia’s market cap?
MetaVia’s market cap is $12.51M.
When is MetaVia’s upcoming earnings report date?
MetaVia’s upcoming earnings report date is Mar 26, 2026 which is in 69 days.
How were MetaVia’s earnings last quarter?
MetaVia released its earnings results on Nov 06, 2025. The company reported -$1.54 earnings per share for the quarter, beating the consensus estimate of -$2.75 by $1.21.
Is MetaVia overvalued?
According to Wall Street analysts MetaVia’s price is currently Undervalued.
Does MetaVia pay dividends?
MetaVia does not currently pay dividends.
What is MetaVia’s EPS estimate?
MetaVia’s EPS estimate is -1.9.
How many shares outstanding does MetaVia have?
MetaVia has 2,308,294 shares outstanding.
What happened to MetaVia’s price movement after its last earnings report?
MetaVia reported an EPS of -$1.54 in its last earnings report, beating expectations of -$2.75. Following the earnings report the stock price went down -15%.
Which hedge fund is a major shareholder of MetaVia?
Currently, no hedge funds are holding shares in MTVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MetaVia
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
MTVA Stock 12 Month Forecast
Average Price Target
$47.50
▲(776.38% Upside)